124 related articles for article (PubMed ID: 21273759)
1. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
7. LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy.
Long XH; Zhong ZH; Peng AF; Zhu LB; Wang H; Zhang GM; Liu ZL
Mol Med Rep; 2014 Dec; 10(6):2967-72. PubMed ID: 25310590
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
McDonald GT; Sullivan R; Paré GC; Graham CH
Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
[TBL] [Abstract][Full Text] [Related]
9. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
10. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
11. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
13. Silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway.
Feng N; Luo J; Guo X
Mol Med Rep; 2016 Apr; 13(4):3243-8. PubMed ID: 26936429
[TBL] [Abstract][Full Text] [Related]
14. Cordycepin induces apoptosis in human bladder cancer T24 cells through ROS-dependent inhibition of the PI3K/Akt signaling pathway.
Kim SO; Cha HJ; Park C; Lee H; Hong SH; Jeong SJ; Park SH; Kim GY; Leem SH; Jin CY; Hwang EJ; Choi YH
Biosci Trends; 2019; 13(4):324-333. PubMed ID: 31527329
[TBL] [Abstract][Full Text] [Related]
15. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
Xu R; Nakano K; Iwasaki H; Kumagai M; Wakabayashi R; Yamasaki A; Suzuki H; Mibu R; Onishi H; Katano M
Cancer Lett; 2011 Jul; 306(2):151-60. PubMed ID: 21429662
[TBL] [Abstract][Full Text] [Related]
17. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587
[TBL] [Abstract][Full Text] [Related]
18. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
Abdul-Ghani R; Serra V; Györffy B; Jürchott K; Solf A; Dietel M; Schäfer R
Oncogene; 2006 Mar; 25(12):1743-52. PubMed ID: 16288223
[TBL] [Abstract][Full Text] [Related]
19. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway.
Fu ZY; Lv JH; Ma CY; Yang DP; Wang T
Biomed Pharmacother; 2011 Jun; 65(3):163-7. PubMed ID: 21684102
[TBL] [Abstract][Full Text] [Related]
20. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.
Liu S; Li Y; Lin T; Fan X; Liang Y; Heemann U
Diabetes Res Clin Pract; 2011 Feb; 91(2):177-82. PubMed ID: 21129803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
